| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a naturally occurring naphthoquinone derivative. –Plumbagin can undergo redox cycling to generate reactive oxygen species (ROS) -apototosis, activation of caspases, modulation of Bax, Bcl‑2, loss of MMP. -Cell cycle arrest in cancer cells, often at the G0/G1, or G2/M phases. -May inhibit NF‑κB activation – MAPK Pathways – PI3K/Akt Pathway -Downregulation of (VEGF) and matrix metalloproteinases (MMPs). -Seems capable of raising ROS in normal and cancer cells (#2004) -ic50 cancer cells 1-10uM, normal cells >10uM
|
| Source: |
| Type: |
| When cyclin B levels are elevated, cells can enter M phase prematurely and strict control over cell division is lost, which is favorable for cancer development. Cyclin B is a regulatory protein that plays a crucial role in cell cycle progression, particularly in the transition from the G2 phase to mitosis. Its expression levels can significantly impact cancer progression and patient prognosis. Cyclin B expression is often elevated in various cancers and is generally associated with poor prognosis. Cyclin B levels: -Accumulate during S and G2 -Peak at mitotic entry -Are rapidly destroyed at metaphase–anaphase transition via the APC/C ubiquitin ligase |
| 5161- | PLB, | Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
| 5162- | PLB, | Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells |
| - | vitro+vivo, | Melanoma, | A172 |
| 5163- | PLB, | Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:299 Target#:379 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid